Discovery of Dengue Virus NS4B Inhibitors

• Published in: Journal of virology Vol. 89; no. 16; pp. 8233 - 8244
• Main Authors: Wang, Qing-Yin, Dong, Hongping, Zou, Bin, Karuna, Ratna, Wan, Kah Fei, Zou, Jing, Susila, Agatha, Yip, Andy, Shan, Chao, Yeo, Kim Long, Xu, Haoying, Ding, Mei, Chan, Wai Ling, Gu, Feng, Seah, Peck Gee, Liu, Wei, Lakshminarayana, Suresh B, Kang, CongBao, Lescar, Julien, Blasco, Francesca, Smith, Paul W, Shi, Pei-Yong
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 01.08.2015
• Subjects: Animals; Antiviral Agents - pharmacology; Cell Line; Cricetinae; Dengue virus; Dengue Virus - drug effects; Drug Discovery; Humans; Spiro Compounds - chemistry; Spiro Compounds - pharmacology; Spotlight; Vaccines and Antiviral Agents; Viral Nonstructural Proteins - antagonists & inhibitors
• ISSN: 0022-538X; 1098-5514
• DOI: 10.1128/jvi.00855-15

The four serotypes of dengue virus (DENV-1 to -4) represent the most prevalent mosquito-borne viral pathogens in humans. No clinically approved vaccine or antiviral is currently available for DENV. Here we report a spiropyrazolopyridone compound that potently inhibits DENV both in vitro and in vivo. The inhibitor was identified through screening of a 1.8-million-compound library by using a DENV-2 replicon assay. The compound selectively inhibits DENV-2 and -3 (50% effective concentration [EC50], 10 to 80 nM) but not DENV-1 and -4 (EC50,>20 M). Resistance analysis showed that a mutation at amino acid 63 of DENV-2 NS4B (a nonenzymatic transmembrane protein and a component of the viral replication complex) could confer resistance to compound inhibition. Genetic studies demonstrate that variations at amino acid 63 of viral NS4B are responsible for the selective inhibition of DENV-2 and -3. Medicinal chemistry improved the physicochemical properties of the initial “hit” (compound 1), leading to compound 14a, which has good in vivo pharmacokinetics. Treatment of DENV-2-infected AG129 mice with compound 14a suppressed viremia, even when the treatment started after viral infection. The results have proven the concept that inhibitors of NS4B could potentially be developed for clinical treatment of DENV infection. Compound 14a represents a potential preclinical candidate for treatment of DENV-2- and -3-infected patients.